Adma Biologics (ADMA) Registers a Bigger Fall Than the Market: Important Facts to Note

Adma Biologics (ADMA) closed the most recent trading day at $15.59, moving -4.24% from the previous trading session. The stock fell short of the S&P 500, which registered a loss of 1.57% for the day. Elsewhere, the Dow lost 1.34%, while the tech-heavy Nasdaq lost 2.04%.

The infectious disease drug developer's shares have seen a decrease of 10.94% over the last month, not keeping up with the Medical sector's loss of 0.8% and the S&P 500's loss of 0.29%.

Analysts and investors alike will be keeping a close eye on the performance of Adma Biologics in its upcoming earnings disclosure.

Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $0.57 per share and revenue of $0 million, indicating changes of +16.33% and 0%, respectively, compared to the previous year.

Investors might also notice recent changes to analyst estimates for Adma Biologics. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.

Our research shows that these estimate changes are directly correlated with near-term stock prices. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.

Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 3.66% increase. Adma Biologics is holding a Zacks Rank of #2 (Buy) right now.

With respect to valuation, Adma Biologics is currently being traded at a Forward P/E ratio of 19.15. This signifies a discount in comparison to the average Forward P/E of 19.61 for its industry.

The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 86, finds itself in the top 36% echelons of all 250+ industries.

The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

You can find more information on all of these metrics, and much more, on Zacks.com.

5 Stocks Set to Double

Each was handpicked by a Zacks expert as the favorite stock to gain +100% or more in the months ahead. They include

Stock #1: A Disruptive Force with Notable Growth and Resilience

Stock #2: Bullish Signs Signaling to Buy the Dip

Stock #3: One of the Most Compelling Investments in the Market

Stock #4: Leader In a Red-Hot Industry Poised for Growth

Stock #5: Modern Omni-Channel Platform Coiled to Spring

Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. While not all picks can be winners, previous recommendations have soared +171%, +209% and +232%.

See Our Newest 5 Stocks Set to Double Picks >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

ADMA Biologics Inc (ADMA): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research